Figure 4.

(A) Relationship of Gleason categories with Gleason 7 separated into 3 + 4 and 4 + 4 with biochemical recurrence, (B) “quantitative” Gleason with patient groups defined by the fraction of Gleason 4. Association between ADAM15 expression and biochemical recurrence in (C) all cancers, (D) ERG fusion negative cancers and (C) ERG fusion positive cancers. (D) Prognostic impact depending on patterns of coalterations of ADAM15 and PTEN. ADAM15 “low” indicates tumors with negative, weak or moderate expression; ADAM15 “high” indicates tumors with strong expression.